- Australian researchers have reported the transmission of an HIV strainwhich was resistant to both Glaxo Wellcome's nucleoside reverse transcriptase inhibitor zidovudine and Boehringer Ingelheim's non-nucleoside RTI nevirapine, according to The Journal of Infectious Diseases (June issue). This is believed to be the first documented case of transmission of HIV-1 resistant to two antiretroviral agents, and emphasizes the need to investigate different combinations of drugs which act at different sites of the HIV life cycle, say the authors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze